Julie Jaffray

Julie Jaffray

Auto-generated profile, based on publicly available information

Julie Jaffray

Department of Pediatrics, University of California, San Diego, San Diego, CA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2021 in Blood
Verified
Journal Article
Open access
PDF file
HWHilary Baker Whitworth
Hilary Baker Whitworth
SSSarah E. Sartain
Sarah E. Sartain
RKRiten Kumar
Riten Kumar
KAKatherine Armstrong
Katherine Armstrong
LBLance Ballester
Lance Ballester
LRLeslie Raffini
Leslie Raffini
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with thrombotic complications in adults, but the incidence of COVID-19-related thrombosis in children and adolescents is unclear. Most children with acute COVID-19 have mild disease, but coagulopathy has been associated with multisystem inflammatory syndrome in children (MIS-C), a postinfectious complication. We conducted a multicenter retrospective cohort study to determine the incidence of thrombosis in children hospitalized with COVID-19 or MIS-C and evaluate associated risk factors. We classified patients into 1 of 3 groups for analysis: COVID-19, MIS-C, or asymptomatic SARS-CoV-2. Among a total of 853 admissions (COVID-19, n = 426; MIS-C, n = 138; and asymptomatic SARS-CoV-2, n = 289) in 814 patients, there were 20 patients with thrombotic events (TEs; including 1 stroke). Patients with MIS-C had the highest incidence (9 [6.5%] of 138) vs COVID-19 (9 [2.1%] of 426) or asymptomatic SARS-CoV-2 (2 [0.7%] of 289). In patients with COVID-19 or MIS-C, a majority of TEs (89%) occurred in patients age ≥12 years. Patients age ≥12 years with MIS-C had the highest rate of thrombosis at 19% (9 of 48). Notably, 71% of TEs that were not present on admission occurred despite thromboprophylaxis. Multivariable analysis identified the following as significantly associated with thrombosis: age ≥12 years, cancer, presence of a central venous catheter, and MIS-C. In patients with COVID-19 or MIS-C, hospital mortality was 2.3% (13 of 564), but it was 28% (5 of 18) in patients with TEs. Our findings may help inform pediatric thromboprophylaxis strategies.

27 May 2025 in Blood Advances
Verified
Journal Article
Open access
PMPaul Monagle
Paul Monagle
MAMuayad Azzam
Muayad Azzam
RBRachel Bercovitz
Rachel Bercovitz
MBMarisol Betensky
Marisol Betensky
RBRukhmi Bhat
Rukhmi Bhat
RMReem A. Mustafa
Reem A. Mustafa
Background: The American Society of Hematology (ASH) guidelines on treatment of pediatric venous thromboembolism (VTE) were published in 2018. In the last 6 years, there has been a 10-fold increase in the number of children involved in VTE treatment trials. Objective: The ASH Committee on Quality and Guidelines agreed to update the pediatric guidelines in conjunction with the International Society on Thrombosis and Haemostasis (ISTH). These ASH/ISTH evidence-based guidelines are intended to support patients, clinicians, and other health care professionals in the management of pediatric patients with VTE. Methods: ASH/ISTH formed a multidisciplinary guideline panel to minimize potential bias from conflicts of interest. An unconflicted patient representative was not identified. The University of Kansas Health System supported the guideline development process, updating or performing systematic evidence reviews up to 2024. The panel focused specifically on the 2018 questions for which there was the greatest amount of interim data. The panel used the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. Results: The panel agreed on 20 recommendations and also provided implementation guidance on the optimal use of anticoagulants in pediatric patients. Key recommendations of these guidelines include the role of DOACs in the treatment of a variety of pediatric VTEs. Conclusions: Further research is required. Key priorities are understanding the natural history of clinically unsuspected thrombosis across a range of patient subpopulations and obtaining real-world data on the use of DOACs in children.

1 September 2017 in Thrombosis Research
Verified
Journal Article
Closed access
LKLisa Baumann Kreuziger
Lisa Baumann Kreuziger
JJJulie Jaffray
Julie Jaffray
MCMarc Carrier
Marc Carrier

1 January 2018 in Thrombosis Research
Verified
Journal Article
Closed access
JJJulie Jaffray
Julie Jaffray
AMArash Mahajerin
Arash Mahajerin
GYGuy Young
Guy Young
NGNeil Goldenberg
Neil Goldenberg
LJLingyun Ji
Lingyun Ji
BBBrian Branchford
Brian Branchford

16 January 2020 in Blood
Verified
Journal Article
Closed access
PDF file
JJJulie Jaffray
Julie Jaffray
CWChar Witmer
Char Witmer
SOSarah H. O’bRien
Sarah H. O’bRien
RDRosa Diaz
Rosa Diaz
Lingyun JiLingyun Ji
Lingyun Ji
GYGuy Young
Guy Young
Venous thromboembolism (VTE) incidence in children has sharply increased with the majority of cases secondary to central venous catheters (CVCs). Among CVCs, the number of peripherally inserted central catheters (PICCs) placed has risen significantly. In this multicenter, prospective, observational cohort study, we enrolled patients aged 6 months to 18 years with newly placed PICCs or tunneled lines (TLs). We evaluated the incidence of VTE, central line–associated bloodstream infections (CLABSIs), and catheter malfunctions in PICCs and TLs, and risk factors of CVC-related VTE. A total of 1967 CVCs were included in the analysis. The incidence of CVC-related VTE was 5.9% ± 0.63%. The majority of the cases, 80%, were in subjects with PICCs, which had a significantly higher risk of catheter-related VTE than subjects with TLs (hazard ratio [HR] = 8.5; 95% confidence interval [CI], 3.1-23; P < .001). PICCs were significantly more likely to have a CLABSI (HR = 1.6; 95% CI, 1.2-2.2; P = .002) and CVC malfunction (HR = 2.0; 95% CI, 1.6-2.4; P < .001). Increased risk of CVC-related VTE was found in patients with a prior history of VTE (HR = 23; 95% CI, 4-127; P < .001), multilumen CVC (HR = 3.9; 95% CI, 1.8-8.9; P = .003), and leukemia (HR = 3.5; 95% CI, 1.3-9.0; P = .031). Children with PICCs had a significantly higher incidence of catheter-related VTE, CLABSI, and CVC malfunction over TLs. The results suggest that pause be taken prior to placing CVCs, especially PICCs, due to the serious complications they have been shown to cause.

23 January 2017 in Frontiers in Pediatrics
Verified
Journal Article
Open access
JJJulie Jaffray
Julie Jaffray
MBMary Bauman
Mary Bauman
PMPatti Massicotte
Patti Massicotte
The use of central venous catheters (CVCs) in children is escalating, which is likely linked to the increased incidence of pediatric venous thromboembolism (VTE). In order to better understand the specific risk factors associated with CVC-VTE in children, as well as available prevention methods, a literature review was performed. The overall incidence of CVC-VTE was found to range from 0% to 74%, depending on the patient population, CVC type, imaging modality and study design. Throughout the available literature, there was not a consistent determination regarding whether a particular type of central line (tunneled versus non-tunneled versus peripherally inserted versus implanted), catheter material, insertion technique or insertion location lead to an increased VTE risk. The patient populations who were found to be most at-risk for CVC-VTE were those with cancer, congenital heart disease, gastrointestinal failure, systemic infection, intensive care unit admission or involved in a trauma. Both mechanical and pharmacological prophylactic techniques have been shown to be successful in preventing VTE in adult patients, but studies in children have yet to be performed or are underpowered. In order to better determine true CVC-VTE risk factors and best preventative techniques, an increase in large, prospective pediatric trials needs to be performed.